Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Deals roundup: Coherus sharpens oncology focus, BridgeBio bolsters balance sheet and more

BioCentury’s weekly roundup of biopharma deals, Jan. 16-22

January 23, 2024 1:32 AM UTC

The decision by Coherus BioSciences Inc. (NASDAQ:CHRS) to divest eye disease therapy Cimerli, a biosimilar of ranibizumab, will further sharpen the biotech’s focus on its core area of oncology.  Sandoz Group AG (SIX:SDZ; Pink:SDZNY) agreed to purchase the asset for $170 million in upfront cash.

The deal, which is expected to close this half, is part of Coherus’ plan to monetize its non-core assets to pay down debt, reduce interest costs and narrow its therapeutic focus. The divestiture will also reduce headcount and overhead costs, the company said. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article